Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: Results of a prospective longitudinal observational study

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 9, 2014, Pages 1186-1191

  Montaudie H ^a   Albert Sabonnadiere C ^a   Acquacalda, E ^a   Fontas, E ^b   Danre A ^a   Roux, C ^a   Ortonne, J P ^a   Lacour, J P ^a   Euller Ziegler, L ^a   Passeron, T ^a,c  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b University of Côte d'Azur   (France)

^c CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CHOLESTEROL; CYCLOSPORIN; ETANERCEPT; ETRETIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; TRIACYLGLYCEROL; URIC ACID; USTEKINUMAB; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GUTTATE PSORIASIS; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MALE; METABOLIC PARAMETERS; MICROALBUMINURIA; NAIL DISEASE; NAIL PSORIASIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; SMOKING; SYSTEMIC THERAPY; TREATMENT RESPONSE; WEIGHT GAIN; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMPLICATION; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME;

ADULT; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84906934910     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12255     Document Type: Article

References (24)

1. Gerdes S, Rostami-Yazdi M, Mrowietz U,. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-87.
2. Cheng J, Kuai D, Zhang L, Yang X, Qiu B,. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012; 304: 119-125.
3. Mallbris L, Granath F, Hamsten A, Ståhle M,. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.
4. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M,. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
5. Gisondi P, Tessari G, Conti A, et al,. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
6. Armesto S, Coto-Segura P, Osuna CG, Camblor PM, Santos-Juanes J,. Psoriasis and hypertension: a case-control study. J Eur Acad Dermatol Venereol 2012; 26: 785-788.
7. Miele L, Vallone S, Cefalo C, et al,. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
8. Gisondi P, Targher G, Zoppini G, Girolomoni G,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
9. Xu T, Zhang Y,. Association of psoriasis with stroke and myocardial infarction: meta analysis of cohort studies. Br J Dermatol 2012; 167: 1345-1350.
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH,. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
11. Scirica BM, Morrow DA,. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113: 2128-2134.
12. Hansson GK,. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
13. Ridker PM, Cannon CP, Morrow D, et al,. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
14. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, et al,. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol 2012; 22: 337-344.
15. Ridker PM,. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
16. Bilhorn KR, Luo Y, Lee BT, Wong ND,. High-density lipoprotein cholesterol, high-sensitivity c-reactive protein, and cardiovascular disease in united states adults. Am J Cardiol 2012; 110: 1464-1467.
17. Wu JJ, Poon K-YT, Channual JC, Shen AY-J,. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148: 1244-1250.
18. Boehncke S, Salgo R, Garbaraviciene J, et al,. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.
19. Strober B, Teller C, Yamauchi P, et al,. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-330.
20. Romaní J, Caixàs A, Carrascosa JM, Ribera M, Rigla M, Luelmo J,. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol 2012; 166: 1237-1244.
21. Marra M, Campanati A, Testa R, et al,. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731-736.
22. Wambier CG, Foss-Freitas MC, Paschoal RS, et al,. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol 2009; 60: 883-885.
23. Martínez-Abundis E, Reynoso-von Drateln C, Hernández- Salazar E, González-Ortiz M,. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007; 299: 461-465.
24. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK,. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006; 166: 902-908.